In order to test the aims/goals of STATIC, we are testing two different ways of taking ibrutinib. Participants of the trial will be randomly assigned to one of two treatment groups:
- 1. Pausing Ibrutinib
Participants in this group take a scheduled break from ibrutinib, and only restart if their CLL gets worse. If restarting ibrutinib controls the CLL again, participants will be able to take another break from treatment.
- 2. Continuous Ibrutinib
Participants in this group continue to take ibrutinib every day.
Participants will continue ibrutinib without a break as long as they are benefitting from it.